Heller Dennis P, Burke Steven K, Davidson David M, Donovan Joanne M
Pharmaceutical Profiles, Princeton, NJ 08540-5700, USA.
Ann Pharmacother. 2002 Mar;36(3):398-403. doi: 10.1345/aph.1A143.
To assess whether colesevelam hydrochloride is absorbed in healthy volunteers.
A single-center, open-label, radiolabeled study was performed with 16 healthy volunteers. Subjects were administered non-radiolabeled colesevelam hydrochloride 1.9 g twice daily for 4 weeks, followed by a single dose of [14C]-colesevelam 2.4 g (480 pCi). These subjects continued to receive non-radioactive colesevelam 1.9 g twice daily for 4 days after administration of the radiolabeled dose. Blood, urine, and feces were collected immediately prior to administration of [14C]-colesevelam and at specified intervals after administration. The whole-blood equivalent concentration of colesevelam was calculated using data collected throughout the 96 hours following radiolabeled drug administration. The proportion of [14C]-colesevelam excreted through urine or feces was calculated based on the amount of radioactivity recovered up to 216 hours after the radiolabeled dose.
The mean cumulative total recovery of [14C]-colesevelam in urine and feces was 0.05% and 74%, respectively. Excluding 2 subjects for whom cumulative recovery was <25%, the mean cumulative fecal recovery was 82%. The mean maximum whole-blood equivalent concentration of colesevelam was 0.165+/-0.10 microg equiv/g 72 hours after administration of [14C]-colesevelam, which was estimated to be 0.04% of the administered dose. All blood samples contained <4 times the number of background counts (dpm).
The cumulative recovery data in urine and feces are consistent with the conclusion that colesevelam is not absorbed and is excreted entirely through the gastrointestinal system.
评估盐酸考来维仑在健康志愿者体内是否被吸收。
对16名健康志愿者进行了一项单中心、开放标签、放射性标记研究。受试者每日两次服用1.9克非放射性盐酸考来维仑,持续4周,随后单次服用2.4克[14C] - 考来维仑(480微居里)。在给予放射性标记剂量后,这些受试者继续每日两次服用1.9克非放射性考来维仑,持续4天。在给予[14C] - 考来维仑之前以及给药后的特定时间间隔采集血液、尿液和粪便。使用放射性标记药物给药后96小时内收集的数据计算考来维仑的全血等效浓度。根据放射性标记剂量后216小时内回收的放射性活度计算通过尿液或粪便排泄的[14C] - 考来维仑的比例。
尿液和粪便中[14C] - 考来维仑的平均累积总回收率分别为0.05%和74%。排除2名累积回收率<25%的受试者后,粪便的平均累积回收率为82%。给予[14C] - 考来维仑72小时后,考来维仑的平均最大全血等效浓度为0.165±0.10微克当量/克,估计为给药剂量的0.04%。所有血样中的计数均<背景计数(每分钟衰变数)的4倍。
尿液和粪便中的累积回收率数据与考来维仑不被吸收且完全通过胃肠道系统排泄的结论一致。